Arrowhead Pharmaceuticals Inc
(NAS:ARWR)
$
25.5
1.71 (7.19%)
Market Cap: 3.17 Bil
Enterprise Value: 2.76 Bil
PE Ratio: 0
PB Ratio: 6.54
GF Score: 54/100 - Q1 2024 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptFeb 06, 2024$33.2 (+3.69%)Earnings
- Arrowhead Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Q4 2023 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptNov 29, 2023$28.98 (+0.21%)Earnings
- Arrowhead Pharmaceuticals Inc Analyst and Investor Event on Plozasiran and Zodasiran (Virtual) TranscriptNov 13, 2023
- Arrowhead Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- Q3 2023 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2023$30.81 (-2.65%)Earnings
- Arrowhead Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Arrowhead Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Arrowhead Pharmaceuticals Inc R&D Day TranscriptJun 01, 2023
- Q2 2023 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptMay 02, 2023$35.38 (-0.95%)Earnings
- Q1 2023 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptFeb 06, 2023$33.51 (-8.79%)Earnings
- Arrowhead Pharmaceuticals Inc to Present Topline Data from the Phase 2 SEQUOIA Study TranscriptJan 09, 2023
- Q4 2022 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptNov 28, 2022$28 (-5.08%)Earnings
- Arrowhead Pharmaceuticals Inc Analyst and Investor Event TranscriptNov 09, 2022
- Q3 2022 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2022$46.13 (+3.99%)Earnings
- Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Arrowhead Pharmaceuticals Inc Pulmonary R&D Day TranscriptMay 26, 2022
- Arrowhead Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 25, 2022
- Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference TranscriptMay 17, 2022
- Arrowhead Pharmaceuticals Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q2 2022 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptMay 10, 2022$34.29 (+4.80%)Earnings
- Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMar 17, 2022
- Q1 2022 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptFeb 02, 2022$52.63 (-4.48%)Earnings
- Q4 2021 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptNov 22, 2021$69.28 (-2.57%)Earnings
- Arrowhead Pharmaceuticals Inc ARO-C3 KOL Webinar TranscriptOct 26, 2021
- Arrowhead Pharmaceuticals Inc at H C Wainwright NASH Investor Conference (Virtual) TranscriptOct 12, 2021
- Q3 2021 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2021$68.05 (+2.92%)Earnings
- Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Arrowhead Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference TranscriptMay 26, 2021
- Q2 2021 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2021$66.48 (-5.35%)Earnings
- Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMar 18, 2021
- Q1 2021 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptFeb 04, 2021$83.92 (+4.47%)Earnings
- Q4 2020 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptNov 23, 2020$68.2 (-0.87%)Earnings
- Arrowhead Pharmaceuticals Inc Key Opinion Leader Webinar on ARO-ANG3 TranscriptNov 19, 2020
- Arrowhead Pharmaceuticals Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 19, 2020
- Arrowhead Pharmaceuticals Inc Key Opinion Leader Webinar on ARO-APOC3 TranscriptNov 18, 2020
- Arrowhead Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd Collaboration and Licensing Agreement to Develop ARO-AAT Conference Call TranscriptOct 08, 2020
- Q3 2020 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2020$43.56 (-1.27%)Earnings
- Arrowhead Pharmaceuticals Inc Key Opinion Leader Webinar on ARO-ENaC TranscriptJul 28, 2020
- Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2020
- Arrowhead Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Q2 2020 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020$35.13 (+2.63%)Earnings
- Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMar 19, 2020
- Arrowhead Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 11, 2020
- Q1 2020 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptFeb 05, 2020$43.72 (-0.41%)Earnings
- Q4 2019 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptNov 25, 2019$56.99 (+15.83%)Earnings
- Arrowhead Pharmaceuticals Inc Analyst R&D Day TranscriptOct 18, 2019
- Q3 2019 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2019$27.24 (-6.46%)Earnings
- Arrowhead Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 15, 2019
- Q2 2019 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2019$18.33 (+1.78%)Earnings
- Arrowhead Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMar 14, 2019
- Arrowhead Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 12, 2019
- Q1 2019 Arrowhead Pharmaceuticals Inc Earnings Call TranscriptFeb 07, 2019$13.3 (-3.90%)Earnings
Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 17, 2022 / 08:35PM GMT
Release Date Price:
$35.77
(+8.79%)
Luca Issi
RBC Capital Markets - Analyst
Great. Thanks. Hello, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets. And today, it's our great privilege to have Arrowhead Pharma here with us for a fireside chat. Representing the company, we have Vince Anzalone, Head of IR. Vince, thanks again for joining us. How are you doing today?
Vince Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR
Great. Thank you, Luca, and thank you to the whole RBC team for having us today. Great day. Thank you.
Questions & Answers
Luca Issi
RBC Capital Markets - Analyst
Terrific. Terrific. We have a long list of questions here for individual programs, but, maybe before we talk about individual program, can you just maybe give us a high-level overview of Arrowhead, maybe what progress the organization has made in the last few months, and, most importantly, what's ahead?
Vince Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR
Sure. So I think the way I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)